AlphAIAlphAI — Financial news for AI agents
finance.yahoo.comOCT 82 min read$ANGO

AngioDynamics Shares Fall 4.3% Despite Q1 Earnings Beat and Strong Med Tech Growth

AngioDynamics (ANGO) reported Q1 fiscal 2027 earnings with revenue of $80.9M, beating estimates, driven by 13.2% growth in Med Tech. Adjusted loss was $0.04 per share, narrower than expected. Shares fell 4.3% pre-market despite results, possibly due to tariff refund impact on margins and unchanged guidance.

Original reporting
finance.yahoo.com
Published Oct 8, 2026, 12:19 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 8, 2026, 12:47 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AngioDynamics Shares Fall 4.3% Despite Q1 Earnings Beat and Strong Med Tech Growth — source image
Source · finance.yahoo.com
Decision brief

The 30-second read

$ANGOBearishMed
01

Why it matters

Earnings beat did not translate into price appreciation; investors focus on margin quality and unchanged outlook, leading to a pre‑market sell‑off.

02

Market read

First‑report earnings data for a small‑cap med‑tech company; modest impact on broader market, but relevant for sector specialists.

03

What to watch

Tariff refund boost to gross margin may be non‑recurring; future quarters could see margin compression without such refunds.

Relevance 7/10Novelty 7/10Timing: pre‑market today

Background

AngioDynamics reported Q1 FY2027 results with revenue slightly above estimates, a narrowed loss, and reaffirmed full‑year guidance. Leadership transition announced for November.

Company-level read

Ticker impact

$ANGOBearishHigh confidence
Context

Q1 fiscal 2027 earnings beat expectations but shares fell 4.3% pre‑market; guidance unchanged.

Expected impact

likely further downside as market questions margin quality and unchanged outlook

Evidence & confidence

Earnings beat was modest and margin boost included tariff refunds; unchanged guidance fails to excite investors, prompting a sell‑off.

Market effects

Sector

MedTech segment shows strong growth, may benefit peers with similar product lines.

Regional

U.S. small‑cap healthcare sector could see modest pressure.

Global

Limited; impact confined to niche medical‑technology space.

Counterpoint

What could challenge this read

The earnings beat and double‑digit Med Tech growth could be a buying opportunity if the market overreacts to the short‑term price dip.

Key entities

  • Company
    AngioDynamics Inc.

    Medical technology firm reporting Q1 FY2027 results.

  • Executive
    Eric Honroth

    Incoming CEO effective November 2026.

Read at source← All news

Also covered by

3 outlets

Related articles

OCT 8
$ANGOHighAI 8/10

AngioDynamics Q1 FY2027 net loss narrows to $7.1M

AngioDynamics (NASDAQ: ANGO) reported Q1 FY2027 net loss of $7.1M, down from $10.9M YoY. Net sales rose 6.9% to $80.9M, with Med Tech sales up 13.2%. Adjusted EBITDA was $5.0M. The company announced Eric Honroth as new CEO, effective November 2, 2026. FDA approved IDE for RELIEF study on NanoKnife IRE for benign prostatic hyperplasia. Guidance reiterated: net sales $336M-$341M, adjusted EBITDA $13M-$16M.

stocktitan.net2 min
OCT 8
$ANGOMed

AngioDynamics Reports Fiscal Year 2027 First Quarter Financial Results; Continued Execution Drives Med Tech Growth and Profitability

ANGIODYNAMICS INC (ANGO) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 AngioDynamics Reports Fiscal Year 2027 First Quarter Financial Results; Continued Execution Drives Med Tech Growth and Profitability Delivered its eighth consecutive quarter of double-digit Med Tech segment growth and positive adjusted EBITDA LATHAM, N.Y.--(BUSINESS

SEC EDGAR 8-K2 min
OCT 8
$ANGOLow

AngioDynamics, Inc. (ANGO) Appoints Eric Honroth CEO

AngioDynamics, Inc. (ANGO) named Eric Honroth as President and CEO, effective Nov. 2, 2026. He replaces Jim Clemmer, who will leave the board but stay as a consultant. The company aims to advance its transformation and Med Tech momentum under new leadership, according to the press release.

tradingview.com1 min